Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

9.1%

1 terminated/withdrawn out of 11 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

27%

3 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 3

2(40.0%)

Phase 4

1(20.0%)

5Total

N/A(2)

Phase 3(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT06565793Not Yet Recruiting

A MAajor RAdiation-based PCI Study in STEMI and NSTEMI

Role: collaborator

NCT02486315Completed

Treatment of Coronary ARtery bIfurcation Narrowing by AXxess Stent Implantation

Role: lead

NCT05777551Recruiting

AF Ablation With High Power Short Duration RF

Role: lead

NCT03277976Completed

Pulmonary Vein Isolation Guided by Ablation Index (Ablation Index Registry Study)

Role: lead

NCT04714736Not ApplicableCompleted

DyeVert System and Contrast-induced Acute Kidney Injury

Role: lead

NCT04907890Withdrawn

Long Term Outcomes in COVID-19 Patients Recruited in the CORIST Project

Role: collaborator

NCT01098032Phase 3Completed

RenalGuard System and Contrast Media

Role: lead

NCT04321473Unknown

Registry on Left Main Coronary Artery Bifurcation Percutaneous Intervention

Role: collaborator

NCT02489669Not ApplicableUnknown

Renal Insufficiency Following Contrast Media Administration Trial III

Role: lead

NCT02360020Phase 4Completed

The XLIMUS-DES in Very Complex Lesions

Role: lead

NCT01465503Phase 3Completed

Novel Approaches in Preventing and Limiting Events III Trial (NAPLES III): Bivalirudin in High-risk Bleeding Patients

Role: lead

All 11 trials loaded